StockWatch
·
Biotechnology: Pharmaceutical Preparations
Business UpdateNov 18, 2026, 11:46 AM

NeOnc CEO Buys Shares; Clinical Trial Shows Improved Response Rate

AI Summary

NeOnc Technologies Holdings, Inc. announced two key updates. First, Executive Chairman, President, and CEO Amir F. Heshmatpour purchased an additional 30,000 shares of common stock, bringing his year-to-date purchases to 371,000 shares for over $1.5 million. Second, the company reported updated interim results from its Phase 2a clinical study of intranasal NEO100, showing an increased objective response rate of 12.5% (3 of 24 patients) compared to previous results. The company also furnished presentation materials detailing its operations and clinical development, including these updated study results.

Key Highlights

  • CEO Amir F. Heshmatpour purchased 30,000 shares of NeOnc common stock on November 13, 2026.
  • CEO's year-to-date open-market purchases total 371,000 shares, exceeding $1.5 million.
  • Updated Phase 2a study results for intranasal NEO100 show an objective response rate of 12.5% (3 of 24 patients).
  • This represents an increase from the previous objective response rate of 8.3% (2 of 24 patients).
  • The company is preparing for an End-of-Phase 2 meeting with the FDA in January 2027 regarding NEO100.